Do you want to read an article? Please log in or register.
LBA3: LIBRETTO-432: Adjuvant selpercatinib significantly improved EFS in early-stage RET fusion-positive NSCLC
Lung, Respiratory and Thoracic Cancer
CHICAGO 2026
Related content
ESMO 2025
Breast Cancer
monarchE: Adjuvant abemaciclib plus ET significantly improves OS in high-risk HR-positive, HER2-negative early breast cancer
WCLC 2025
Lung, Respiratory and Thoracic Cancer
KEYNOTE-671: Perioperative pembrolizumab improves efficacy outcomes regardless of nodal status in patients with early-stage NSCLC
ESMO 2025
Breast Cancer
DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer
ESMO 2025
Breast Cancer
LBA1: DESTINY-Breast05: T-DXd significantly improves IDFS and DFS versus T-DM1 in HER2-positive early breast cancer with residual invasive disease
CHICAGO 2026
Breast Cancer
KEYNOTE-522: Pembrolizumab plus chemotherapy provides sustained EFS and OS benefits at 8-year follow-up in high-risk early-stage TNBC
RECOMMENDED
Breast Cancer
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial
★ 3
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol
Chen X, Huang J, Shi H, Zhu J, Wu W, Ye G, He Q, Shi Y, Zhang A, Xie X, Wang X, Chen X, Wu W, Wu J, Li Z, Li Z, Dai Y, Ren W, Shao Q, Chen Y, Zeng Y, Zhang F, Dong S, Pegram MD, Shen K
doi: 10.1200/JCO-25-02412
Lung, Respiratory and Thoracic Cancer
Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study
Lung Cancer
Supiot R, Gherardi A, du Manoir de Juaye L, Doghri O, Sivignon M, Duruisseaux M, Chouaid C
doi: 10.1016/j.lungcan.2025.108885
Lung, Respiratory and Thoracic Cancer
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial
Lung Cancer
Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL
doi: 10.1016/j.lungcan.2026.109385
Breast Cancer
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis
Lancet Oncol
Villacampa G, Pascual T, Tarantino P, Cortés J, Perez-García J, Llombart-Cussac A, Conte P, Mancino M, Guarneri V, Dieci MV, Waks AG, Schettini F, Brasó-Maristany F, Griguolo G, de Castro BA, Reboredo C, Antolín S, Bueno-Muiño C, Echavarría I, López-Tarruella S, Massarrah T, Del Monte-Millán M, Martín M, Buckingham W, Parker JS, Vivancos A, Polyak K, Filho OM, Wolff AC, DeMichele A, Tung NM, Perou CM, Paré L, Villagrasa P, Prat A, Tolaney SM
doi: 10.1016/S1470-2045(25)00276-1